Recruiting PHASE3 INTERVENTIONAL 3-arm NCT06318169

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Sponsor: 89bio, Inc.

Conditions Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Interventions Pegozafermin Placebo

Updated 21 times since 2024 Last updated: Feb 9, 2026 Started: Mar 13, 2024 Primary completion: Feb 28, 2029 Completion: Feb 28, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis, this trial is actively recruiting participants. The trial is conducted by 89bio, Inc. and has accumulated 21 data snapshots since 2024. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

21 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE3
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE3
Sep 2025 — Dec 2025 [monthly]

Recruiting PHASE3

▶ Show 16 earlier versions

Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE3
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE3
May 2025 — Jun 2025 [monthly]

Recruiting PHASE3
Apr 2025 — May 2025 [monthly]

Recruiting PHASE3
Feb 2025 — Apr 2025 [monthly]

Recruiting PHASE3
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE3
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE3
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3

First recorded

Mar 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

89bio, Inc.

Data source: 89bio, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Adelaide, Australia , Afula, Israel , Akron, United States , Albuquerque, United States , Amarillo, United States , Amiens, France , Amsterdam, Netherlands , Angers, France , Ankara, Turkey (Türkiye) and 262 more locations